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The potential of microporous zeolites FAU and BEA, and mesoporous MCM-41, for prolonged release of atenolol in 
drug delivery systems was investigated both experimentally, using drug release studies, and theoretically using 
classical molecular dynamics simulations.  
Remarkably, zero-order release of atenolol was achieved from FAU (SiO2/Al2O3 = 80:1) into phosphate buffer for 24 
hours followed by prolonged release for at least another 48 hours. Experimental data also demonstrate the ability 
for all of the drug-zeolite combinations investigated to achieve prolonged release of atenolol, with the release rates 
determined by the combination of framework topology, aluminium content and drug release study media.  
Molecular dynamics simulations give an insight into the reasons for the different release rates observed for FAU 
and BEA.  The results of this work emphasise the need for sophisticated models in order to model subtle 






Drug Release  




The potential of various inorganic materials as carriers for drugs has been investigated with a view to improving 
efficacy or reducing side-effects. Various ordered microporous and mesoporous silica structures have been the 
subject of recent interest including zeolites (1,2) and mesoporous materials, such as MCM-41(3,4). 
Zeolites are microporous crystalline materials with well-defined structures made from interconnecting SiO4 and AlO4- 
tetrahedra. They have many properties which make them good candidates for drug delivery systems including having 
a unique microporosity, large surface area, large pore volume, narrow pore size distribution, good biocompatibility 
and low toxicity. There are over 150 known distinct structures of zeolites each containing interconnecting pores of 
0.2-2nm diameter and channels of various dimensions that can be large enough to accommodate drug molecules of 
different structures and sizes.  
Zeolites can be produced such that aluminium atoms are included in the framework in place of a proportion of the 
silicon atoms. The aluminium content is described by the silica: alumina (SiO2: Al2O3) ratio i.e. a ratio of 360:1 indicates 
that there are 180 silicon atoms for every aluminium atom. Each aluminium atom in the framework results in a 
negative charge being induced on one of the adjacent oxygen atoms which in turn requires a positively charged 
counter-ion in order to maintain the neutrality of the framework. Common examples of counter-ions include H+, Na+ 
and NH4+. When the counter-ion is hydrogen, Brønsted Acid sites are formed, resulting in a more acidic framework 
than those with lower aluminium content. Alteration of the ratio of aluminium to silicon atoms can be used to 
manipulate the properties of the framework, including hydrophobicity/ hydrophilicity, charge and acidity, both within 
the internal channel system and on the external surface(2,5-9). 
It has been shown that, if zeolites are loaded with appropriately selected drug molecules, the release of the drug into 
dissolution media can be modified in order to increase bioavailability, slow down or speed up the release of a 
drug(9,10). Examples of zeolites with distinctly different pore, channel and cage systems that have been investigated 
for use in drug delivery systems include zeolite beta (BEA) and faujasite (FAU). BEA is a 3D system comprised of 
straight and sinusoidal 12 member ring channels (6.7 Å in diameter), while FAU is made up from sodalite cages linked 
by hexagonal prisms to form super cages (13 Å in diameter linked by 7 Å windows) (11). 
Mesoporous materials (pore sizes of 2-50nm), such as MCM-41, also have the ability to modify drug release 
rates(4,12). As with zeolites, MCM-41 can be produced with alumino-substitution of a proportion of the silicon atoms 
in order to manipulate the physicochemical properties of the internal channels and external surface, and MCM-41 
therefore shares the desirable physical properties of zeolites. In addition to these properties it is proposed that, as 
mesoporous materials have a larger pore volume and tuneable pore size, they have the potential to be used as drug 
reservoirs with a large loading capacity(4,13).  
While it is possible to use a combination of drug and zeolite or mesoporous material to produce a modified release 
drug delivery system, selection of an appropriate combination of framework and drug can be difficult and, in order 
to optimise host-drug combinations, it is desirable to have a screening mechanism which is able to identify those 
combinations that are likely to be suitable for experimental testing. Classical Molecular Dynamics (MD) simulations 
have been proposed as a tool for screening drug-zeolite combinations prior to further experimental 
investigations(14,15).  
In this work, commercially available zeolite and mesoporous frameworks with different topologies and SiO2: Al2O3 
ratios (table 1) (11,16-20) have been investigated for their potential use in oral prolonged release drug delivery 
systems for the model drug atenolol.  Atenolol was chosen as a model drug because, due to possessing both polar 
and non-polar regions (figure 1), the interactions with frameworks are difficult to predict. The amount of drug 
released during these experiments is not intended to reflect a therapeutic dose but instead allow insight into factors 




Since all the frameworks being investigated in this study are insoluble in water, the mechanism for modifying the 
drug release rate is likely to be similar to that of a matrix polymer. Accordingly, the release rate will be determined 
by the rate of diffusion of the drug molecule through the framework channels or cages. MD uses simulations to model 
the molecular mobility of the drug molecule within a framework, and comparison of MD simulation results  therefore 
has the potential to predict which drug-framework combinations will release the drug faster or slower in drug release 
studies. One of the aims of this study is to further evaluate the usefulness of the technique by making comparisons 
with the observed experimental data for a molecule with such a mixture of hydrophilic and hydrophobic regions. 
 




Material and Methods 
Materials 
Zeolites were purchased from Alfa Aesar. Mesoporous materials and atenolol were purchased from Sigma Aldrich. 
Acetone (laboratory reagent grade) was purchased from Fisher Chemical. Phosphate buffered saline (pH 7.4) and 
concentrated HCl was purchased from Fisher Scientific. HCl was diluted with deionised water to produce a 0.1M 







The largest diameter of a sphere that 
can diffuse along the channels/ Å 
Specific Surface 
Area/ m2/g 
BEA H+ 360:1 
 
5.95 620 






     
MCM-41 
 
H+ ∞ 21-27 ~1000 
Alumino-MCM-41 H+ 32.3:1 25-30 940-1000 
Table 1 Summary of Zeolites investigated (11, 16-20) 
Preparation of drug loaded zeolites and mesoporous materials 
200mg of zeolite or mesoporous material was soaked for 4 hours at room temperature in a solution of 8mg atenolol 
dissolved in 40 mL acetone. The solvent was then removed by filtration and the solid sample was dried overnight in 
an oven at 70oC before storage in a desiccator prior to analysis. 
Thermogravimetric Analysis  
Thermogravimetric analysis (TGA) was carried out using a TG 209 F1 Libra instrument (Netzsch, Germany), with a 
constant heating rate of 10 oC/min. Nitrogen (50 mL/min flow) was used as inert gas from 25 oC up to 600oC, when 
the carrier was switched to dry air (50 mL/min flow; from 600oC- 800oC) to allow for the combustion of the organic 
residue. Data was processed using Netzsch Proteus v.6.1 analysis software, which was used to include the Derivative 
Thermogravimetric data (DTG). 
Drug Release Studies 
Tablets of the loaded zeolite samples were prepared using a single punch tablet press with a 13mm die under a load 
of 3 tonnes for 30 seconds. The release of atenolol from the tablets was then analysed for 24 hours using USP/ Ph.Eur. 
basket dissolution apparatus (Pharma Test PT-DT7) to measure absorbance at a wavelength of 225nm in HCl 0.1M 
(‘acid’-pH 1.2) and phosphate buffer (‘buffer’-pH 7.4).  FAU 80:1 samples were analysed for a further 48 hours (total 
72 hours) due to drug release extending beyond 24 hours. Calibration curves were plotted to enable absorbance 
values to be converted into drug concentration and calculation of the mass of drug released. A control sample was 
also used during each drug release test and the absorbance values of the control were subtracted from the test 
sample values. All studies were carried out under sink conditions in triplicate and data presented are the average 
values with standard deviation presented as error bars. All reasonable steps were taken to prevent evaporation 




Molecular dynamics simulations 
 
Molecular dynamics calculations were undertaken using the program Materials Studio (21).  A fully siliceous model 
was used for the host frameworks, with no constraints applied to the movement of the atoms.  A 1x1x1 supercell of 
FAU with dimensions (25.028Å x 25.028Å x 25.028Å) and a 4x2x1 supercell of BEA with dimensions of (50.645Å x 
25.323Å x 26.406Å) were used as the simulation box for the zeolite frameworks.  For MCM-41, the model of the 
disordered hydroxylated structure developed by Ugliengo et al was used (22), with a supercell of dimensions 
(40.603Å x 40.603Å x 73.21Å).  Periodic boundary conditions were applied with a loading of one molecule per 
simulation box.  Calculations were performed for 20 000 000 steps with a time step of 1 fs, with the atomic 
coordinates recorded every 20 ps.  The first 500 ps of the run were used to equilibrate the system and this data was 
discarded from the subsequent analysis.  The CVFF forcefield was used in these simulations.  This forcefield was 
chosen as it has been widely used to successfully to simulate the location of organic molecules within zeolite hosts 
(see for example reference 23).  Ewald summation was used to calculate the electrostatic component of the energy, 
while a cut-off of 12.5Å was used for the short-range interactions.  Cartesian coordinates of the atenolol centroid 
were extracted for each recorded frame of the simulation data allowing calculation of the distance travelled between 
each recorded frame.  All simulations were carried out in triplicate and average values are shown in the graphs. 
 
One of the requirements of periodic molecular dynamics calculations is that the overall charge of the system is 
neutral.  For the zeolite systems investigated here, simulations were performed on fully siliceous frameworks where 
the overall charge on the drug and zeolite were both zero (but with appropriate partial charges calculated for the 
individual atoms).  Simulations were also carried out for a protonated atenolol molecule located within a charged (-
1) framework.  This charge was ‘smeared’ across all of the framework oxygen atoms using the charge adjustment 










Figure 2 TGA (solid line) and DTG (dashed line) of a. pure atenolol, b. overlaid unloaded FAU 5.1:1 H+ framework (black) and FAU 5.1:1 H+ 










Table 2 Summary of Final Experimental Drug Loading and Drug Release Values Summary of Final Experimental Drug Loading and Drug 
Release Values. ‘Acid’ is 0.1M HCl pH1.2 and ‘buffer’ is phosphate buffer pH7.4. 
Typical TGA results (for pure atenolol, unloaded FAU 5.1:1 H+, and FAU 5.1:1 H+ loaded with atenolol) are presented 
in figure 2.   The thermogram of pure atenolol (solid line) shows its degradation starts above 260oC, with a residual 
mass at 600oC of less than 20% and followed by the complete combustion of the organic residue. 
The data from the unloaded samples (zeolites only) show a mass change step typically around 100oC, due to the loss 
of physisorbed water from within the frameworks. However, in addition to the initial loss of water, the unloaded 
samples appear to continue to lose mass - very slowly - across the entire temperature range of the experiment. This 
is perhaps not surprising since it is known that zeolites are able to retain water within their frameworks at 
temperatures above the boiling point of water and this minor mass change step may therefore represent continued 
water loss throughout the duration of the experiment(24). No subsequent mass loss associated with high 
temperature combustion was observed after switching to air as a carrier at 600oC. The unloaded mesoporous 
materials do not lose as much water as the unloaded zeolite samples (2-3% vs. 8-20% respectively), reflective of a 
reduced content of physisorbed water in mesoporous materials compared to zeolites. 
The thermograms of the drug loaded samples also show a mass loss step at around 100oC, similar to the unloaded 
samples, due to loss of physisorbed water; additionally, at higher temperatures, a mass loss step associated with 
atenolol degradation can be observed. The loaded drug content was calculated by subtracting the total percentage 
mass loss values above 200oC (mass loss loaded – unloaded).  
Table 2 displays the estimated drug content of the drug loaded zeolite test samples based on TGA data as well as the 
estimated loading efficiency calculated as follows: 
Estimated loading efficiency =  
Actual drug content of loaded zeolite calculated from TGA data (%)
3.84 (= maximum possible drug content of loaded zeolite (%))
 x 100 
The data show that the loading of atenolol into the frameworks is dependent on both the topology and the SiO2: 
Al2O3 ratio of the framework, with greatest loading in frameworks with larger pores and greater aluminium content. 
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Percentage of 
Atenolol Released/ % 
Acid Buffer Acid Buffer 
BEA 
 






















     
MCM-41 
 
3.10 80.6% 1.81 2.00 58.3 64.5 
Alumino-MCM-41 3.83 99.5% 2.89 3.51 75.4 91.6 
9 
 
Drug Release Studies 
 
Figure 3 Comparison of Cumulative Release from Each Framework into HCl 0.1M ‘Acid’ (pH1.2) and Phosphate ‘Buffer’ (pH7.4). Error bars 
shown are standard deviation for all graphs NB: some error bars are very small and obscured by the markers 
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Table 2 summarises the final mass and percentage release of atenolol tests after 24 hours of drug release studies. 
Figure 3 shows the drug release profiles of atenolol from the test samples over 24 hours into ‘acid’ (top) and ‘buffer’ 
(middle) as well as the drug release profile of atenolol from FAU 80:1 into both acid and buffer over 72 hours 
(bottom). 
The results for the release of atenolol from FAU 80:1 into the pH 7.4 phosphate buffer demonstrate that if the correct 
combination of pH, framework topology and SiO2: Al2O3 ratio are used, a zero-order modified release drug delivery 
system can be achieved using a relatively cheap and simple system. The release profile from FAU 80:1 into buffer 
solution is quite remarkable considering the simplicity of the drug delivery system, with linear (R2= 0.9959) release 
for 24 hours, and prolonged release continuing for at least 72 hours. Since transdermal patches, and other drug 
delivery systems, employ the use of a matrix polymer similar to the system investigated here, it is interesting to note 
that it may be possible to formulate a dosage form for routes other than oral delivery such as transdermal delivery 
via a patch which could last for at least 72 hours.  
The result for FAU 80:1 into pH 7.4 phosphate buffer is in stark contrast to other samples which produce a burst 
release at the start of the experiment followed by slower release of the drug. Again, the speed, quantity and duration 
of drug release is determined by the combination of pH, framework topology and SiO2: Al2O3 ratio.  
These results, although not as remarkable as the FAU 80:1 sample described above, demonstrate the potential of a 
range of ordered microporous and mesoporous materials to produce prolonged release drug delivery systems that 
have varying drug release profiles. The potential explanations for the observed results are considered in the 
discussion. 
Also notable from the drug release studies was the observation that the tablets remained intact at the end of the 
experiment and did not break up, dissolve, or disperse. This is a helpful observation to note as, although it is already 
known that the frameworks are insoluble in water, dispersal of the tablets into smaller particles would have increased 
the surface area, introducing another variable that could have affected the drug release rate. Since the tablets are 





Molecular Dynamics Simulations 
 
Figure 4 Figures 4 a-c show the Location of Atenolol Every 400 ps During MD Calculations in b. BEA, c. FAU and d. MCM-41 with the initial 




Figure 5 The average distance travelled against time for the atenolol centroid during the molecular dynamics simulations. Data displayed is 
every 100th data point to allow error bars to be displayed. Error bars shown are standard deviation. 
Figures 4a-c illustrate the movement of the drug molecules during the molecular dynamics simulations, while figure 
5 shows the distance travelled by the centroid of the atenolol molecule against time from MD simulations. Distance 
travelled is presented here in preference to RMS displacement data as the atenolol molecule is often observed to 
reverse direction along a channel during the course of the simulations.  This effect is particularly noticeable in these 
simulations because of the long simulation time and slow movement of the drug within the host lattices.  It is 
particularly the case for the drug molecule within the BEA framework, where the atenolol molecule can spend a 
significant amount of time at a channel intersection before ‘hopping’ to the next channel intersection. In the 
simulations, there is no driving force for the molecule to move preferentially in one direction along the channel, 
unlike the experiments where the external media will exert an influence on the direction of travel of the molecule. 
It is apparent from the illustrations that the movement of the drug molecule is very different within each of the 
frameworks while the simulation data show that the diffusion of the drug molecule is dependent on the framework 
into which it is loaded, movement being much faster in FAU than BEA or MCM-41. In the BEA framework, the 
movement of the drug molecule is limited to travel along one plane because, due to steric hindrance, it is not possible 
for the drug molecule to move from one channel to another adjacent channel via the intersections and accordingly 
the drug molecule is confined to the channel it is placed in at the start of the simulation.  The drug molecule also 
appears to remain resident at channel intersections for prolonged periods of time before ‘hopping’ to another 
adjacent channel intersection.  
The atenolol molecule in the FAU framework simulation demonstrates very different movement to that seen in BEA. 
Unlike the simulation in BEA, the atenolol molecule is able to bend, twist and move freely in all directions within the 
supercages.  It remains in a cage for a period of time until it is suitably aligned to travel through the interlinking 
window into an adjacent supercage. 
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The simulation using the MCM-41 framework demonstrates that surface interaction between the mesopore surface 
and drug molecule presents a significant barrier to drug molecule movement rather than steric hindrance due to 
channel dimensions. It is clear from the MCM-41 simulation data that, despite the absence of steric hindrance, the 
movement of the drug molecule is slower than for the FAU and BEA frameworks.  Since the simulation data are 
reproducible, have narrow standard deviation values, and show that atenolol moves faster in FAU than in BEA, the 
suggested use of MD as a screening tool for predicting effect of steric hindrance and thus release rate on drug-zeolite 
combinations is supported, but the current model does not appear to allow effective comparisons of release rate to 
be made between the microporous and mesoporous structures.  
 
Figure 6 presents a comparison between the average distance travelled for the centroid of the atenolol molecule 
within the two zeolite frameworks when the atenolol molecule is protonated, with the appropriate adjustment to 
the charge of the framework made, as outlined in the method section.  It can be seen that the effects of protonating 
the molecule are relatively small, with only a small change in the rate of movement of the drug molecule inside the 
FAU framework.  A more pronounced effect in observed for BEA, but the rate of movement in this framework is still 
significantly less than in FAU.  The mechanism of movement in the two frameworks remains the same.  
 
Figure 6: Graph to Show Average Cumulative Distance Travelled for Uncharged Atenolol in Uncharged BEA (diamond) and FAU(triangle) 




Effect of Framework Topology 
It is apparent that the choice of framework can have a significant impact on both loading and release 
of atenolol, and this may in part be explained by the effect of steric hindrance on diffusion of the drug 
molecule.  
Steric hindrance of the drug due to limited pore and channel sizes is likely to be greatest in BEA, where 
the largest diameter of a sphere that can diffuse along the channels is just 5.95 Å (16) and there is a 
relatively tight fit of the atenolol molecule with limited movement allowed. The FAU framework will 
also cause steric hindrance, but this will be less because the maximum sphere size that can diffuse 
through the framework is significantly higher at 7.35 Å (16). Importantly, though, the atenolol 
molecule has more room to bend and rotate in FAU than in BEA, particularly within the super cages, 
and thus the effect of steric hindrance should be greater within BEA. These observations agree with 
the experimental data which show that BEA has the lowest loading and lowest relative quantity 
released of all the frameworks into both acid and buffer. The experimental and simulation data for 
drug release rates also agree with this, since drug release in experimental data and drug diffusion in 
simulation data is slower in BEA than in FAU. 
In contrast, the mesoporous materials have much wider pore diameters (21-30 Å)(19,20) which are 
wider than the maximum diameter of the atenolol molecule, and steric hindrance would be unlikely 
to be a significant barrier to drug diffusion. It might follow then that drug loading should be greater 
for all mesoporous materials than for zeolites. However, as the materials have been loaded with only 
a small mass of drug, it is unclear if the frameworks in this study are saturated and is therefore not 
possible to determine if the mesoporous frameworks can load greater quantities of atenolol than 
zeolites. Further investigations are needed to establish whether different experimental conditions can 
result in greater drug loading and determine what mass of drug is loaded when these frameworks are 
saturated.  
If steric hindrance was the only barrier to drug diffusion, it would also be expected that drug release 
would be fastest from the MCM-41 materials. However, it is apparent that release from MCM-41 is 
similar in buffer and slower in acid when compared to release from FAU 5.1:1. This implies that, while 
steric hindrance is a factor in drug release rate, other contributory factors are also significant, 
discussed next. 
Effect of Aluminium Content 
In addition to the effect of framework topology, it is also notable that aluminium content can have a 
significant effect on loading and release from both zeolite and MCM-41 frameworks.  
In the zeolite structures used in this study, H+ ions counter the negative charge introduced to the 
framework by the replacement of silicon atoms by aluminium atoms as the SiO2/Al2O ratio is reduced. 
These H+ ions lead to the formation of Brønsted acid sites with the H+ ions bound to framework oxygen 
atoms adjacent to aluminium.  
The creation of additional Brønsted acid sites as the SiO2/Al2O ratio decreases could, in theory, have 
the potential to either increase or decrease the interaction between the zeolite framework and the 
atenolol molecules.  Increased interaction could result from the formation of hydrogen bonds 
between the drug and the framework.  However, this would result in slower release of the atenolol as 
the SiO2/Al2O ratio is reduced, not the increased rate that is observed in the experiments.  Instead, it 
seems that the additional H+ ions reduce the electrostatic interaction between the framework and the 
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atenolol molecules.  This seems particularly plausible as the atenolol molecule, with a pKa of 9.6 (25), 
will be protonated at both pH =1 and 7.4 resulting in electrostatic repulsion from the framework.  The 
distribution of the Brønsted acid sites in the framework may also be an important factor.  
Furthermore, lower levels of H+ ions at higher SiO2/Al2O ratios may enhance the probability of 
favourable interactions between the drug and Brønsted acid sites, where the H+ ions are more spread 
out along the channels, although the distribution of these sites is a complex issue as aluminium nests 
are known to exist where SiO2/Al2O ratios are high (26,27). 
It should be noted that solvent effects may also provide an explanation for the observed differences 
in drug release at different SiO2/Al2O ratios.  Increased wettability of frameworks with lower SiO2:Al2O3 
ratios(3), means that the sites available for hydrogen bonding may be occupied by water molecules. 
The importance of water molecules at the silica surface has been reported to be of significance in 
MCM-41 loaded with ibuprofen and the authors suggest that this is a consideration that is frequently 
overlooked when investigating drug delivery from silica(28). In addition, there is evidence that 
Brønsted Acid Sites can have mutual interaction via hydrogen bonding and, as a result, greater 
numbers of acid sites do not correlate with greater acidity(29). A combination of these factors may 
result in hydrogen bonding being of a similar strength in frameworks with the same topology 
regardless of the SiO2: Al2O3 ratio.  
 
Effect of pH 
Lastly, the effect of pH on drug release rate is demonstrated. In general, the release of atenolol is 
slower into phosphate buffer than into acid. This implies that the strength of the drug-framework 
interactions present is dependent on the pH and may be due to pH affecting the charge of the 
framework, the drug molecule, water molecules, or a combination of all of these.  
The log P value of atenolol is 0.43, however at pH 1.2 the log D value is -2.817 while at pH 7.4 it is -
1.800 (30) and is therefore protonated at both pH values.  As the pH increases, the Brønsted acid sites 
in the zeolite are more likely to be deprotonated (31). This will lead to a reduction in the electrostatic 
repulsion between the H+ framework ions and the protonated drug molecules.  Hence, faster release 
is observed in a lower pH environment.  Similarly, the charge on the MCM-41 internal surface will be 
more positive in an acid environment, leading to greater electrostatic repulsion between the drug and 
the framework.  It is interesting to note the release from the FAU 5.1:1 sample is much more pH-
dependent than the other samples.  This can be attributed to its higher aluminium content   
It is important to recognise that, given the flattening of the curves in the drug release studies before 
achieving 100% drug release, it is unlikely that all of the drug will be released from the samples. This 
indicates that, while electrostatic repulsion may be a key factor in determining the release rate, there 
must be other drug-framework interactions taking place that are strong enough to prevent release of 
a proportion of the drug molecules. Other authors have suggested possible interactions including 
weak intermolecular hydrogen bonds between silanol groups and drug molecules(32,33), 
coordination complexation (32), and van der Waals forces (33,34). The complex nature of the drug-
framework interactions further highlight the benefits of developing MD simulations and other 






The simulations presented in this work show that MD can be used as a useful predictor of steric 
hindrance for drug-framework combinations, with movement of the drug molecule within the FAU 
structure much faster than BEA.  This suggests that they can usefully be deployed in order to screen 
suitable framework types for prolonged release formulations. MD simulations also yield a unique 
insight into the mechanism of movement of the drug inside the internal channel systems. 
As demonstrated by the experimental data, the presence and strength of drug-framework interactions 
are strongly influenced by both aluminium content and pH.  This emphasises the importance of charge 
in these types of calculation.  The atenolol molecule is protonated, which requires appropriate 
adjustment of the charge of the framework as periodic molecular dynamics simulations require a net 
charge of zero within the simulation box.  Explicit inclusion of counter ions, such as H+ will be important 
in order to use these techniques to predict the influence of SiO2/Al2O ratios on release rates. 
The simulations reported here do not have any solvent molecules in the system. This could help to 
explain why the MD data show atenolol moving slower in MCM-41 than the two zeolite framework 
types. Explicit Inclusion of solvent molecules is likely to be important in release rates, particularly in 
the case of mesoporous materials where the pore volumes are relatively high.  The absence of water 
molecules might also explain why the data show the rate of movement in BEA to be much more similar 
to FAU in MD simulations when compared to lab experiments. This is because, in addition to the drug-
framework interactions that would be occurring, the presence of water may increase the effect of 
steric hindrance, particularly in BEA where there is already a tight fit in the framework channel.  
Including water molecules is feasible, but will increase the computational time significantly, 
particularly in the case of mesoporous materials. 
Only one molecule per simulation box has been included in the simulations reported here.  Again, this 
could be an important limitation, particularly in the case of mesoporous materials where the increased 
pore size means that drug-drug interactions are likely to be more significant. 
The development of simulations which account for all factors that affect drug release rates would be 
extremely desirable since the effect of framework aluminium content and pH are very difficult to 
predict.  Appropriate models will need to explicitly include aluminium atoms, appropriate charge 
balancing cations, such as H+ and solvent molecules in order to help understand the effects of these 





The results presented in this study illustrate the potential of using microporous and mesoporous silica 
for the prolonged release of atenolol. This was most notable with FAU 80:1 which was able to provide 
zero order drug release for over 24 hr into phosphate buffer (used to simulate the conditions of 
intestinal fluid), and continued to slowly release atenolol for a further 48 hr.  It was unexpected that 
this particular combination of zeolite and drug would give rise to such a remarkable release profile 
and hence a screening tool that can identify specific drug-framework combinations that give rise to 
specific release profiles is highly desirable. 
Along with previous studies (13,14), the potential for MD as a screening tool to predict the effect of 
steric hindrance in drug-zeolite combinations is again demonstrated, and it is proposed that MD 
represents a suitable pre-screen for identifying suitable frameworks for delayed release.  However, 
this study highlights that sophisticated models are required in order to predict the effects of changes 
such as SiO2/Al2O ratios or pH.  Including water molecules in the system and explicitly including 
aluminium and counter-ions will be needed to simulate drug-framework interactions more accurately 
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